Who is
Quinta-Analytica?

After graduating from the University of Chemistry and Technology (UCT) in Prague, he worked for 36 years in the pharmaceutical industry. From 1990, he worked as the CEO of the largest pharmaceutical company and founded the new pharmaceutical industry in the Czech Republic. He undergone privatization (MBO) with the company Léčiva (renamed to Zentiva in 2003), carried out three major acquisitions of pharmaceutical companies (Slovakia, Romania, Turkey), carried out the first IPO on the Prague Stock Exchange since 1990 and then left the executive post after the acquisition by the multinational corporation Sanofi. In 2010, he received the Medal of Merit in the Economic Area from the President of the Czech Republic Václav Klaus. He has been a member of management boards of UCT and Charles University Prague since 2010. He is also a member of the advisory body at IOCB Prague, and was a member of BOD of the multinational company Actavis in 2013-2015.

After graduating from the Faculty of Technical and Nuclear Sciences of the Czech Technical University in Prague and postgraduate education at the Institute of Physical Chemistry of the Czechoslovak Academy of Sciences, he worked in various positions at the Research Institute for Pharmacy and Biochemistry in Prague. He later worked for the company Zentiva as the Director and Vice President for Research and Development. In 2011-2015 he was the Chairman of the Control Board of the Grant Agency of the Czech Republic. Today he provides expert consultations in the pharmaceutical industry. He is the author and co-author of more than 50 publications focused on the fields of quantum chemistry, relations between the structure and activity and pharmacokinetics.

Vit is currently acting as an Independent Consultant in the area of Regulatory Science and Clinical Development. Vit is profoundly skilled in the area of Clinical Development strategies/study, design/data mining, scientific support/evaluation, and data interpretation which he gained in multinational pharmaceutical companies, e.g. Pharminvent, Sanofi, Zentiva Inhalation Product and Zentiva. His background includes over 19 years of research experience covering areas of clinical pharmacology and phase I as well as phase II and III studies particularly in inhalation drug development, generic development and pain and obesity management. Educated at the 3rd faculty of medicine in Charles University and resident at the Bulovka hospital department of infectious disease, Vit also served a 3-year tenure as a Postdoctoral Research Fellow at the Health Science Center, University of Tennessee in the US. As a professional, Vit had facilitated the design, strategic development and data mining of bioequivalence, pharmacodynamics and clinical studies which led to numerous, successful market authorizations. Vit is also founder and organizer of BioBridges, a conference platform for professionals from pharmaceutical development, clinical/bioequivalence development and regulatory agencies.

Graduate of Faculty of Chemistry at Moscow State University. He worked at Institute of Macromolecular Chemistry of Czechoslovak Academy of Sciences and at Research Institute for Pharmacy and Biochemistry, Prague where he established laboratory of mass spectroscopy. In 1997 he found the company QUINTA-ANALYTICA s.r.o. where he was acting as a President between 1997-2006. In past he used active member of several scientific societies as J.M. Marci Spectroscopic Society, Czech Mass Spectrometry Group, German Mass Spectrometry Group etc. He is the author and co-author of more than 100 publications focused on the fields of mass spectrometry, trace analysis, analysis of drugs and metabolites and more. During his career, he was appointed as Study Director for more than 350 BE/BA clinical studies. Today he provides expert consultations to QUINTA-ANALYTICA s.r.o. as a member of it's Scientific Advisory Board.

Kay O’Shea holds a BSc degree in Industrial Chemistry from University of Limerick, Ireland, 1987. She has worked for 32 years in the Pharmaceutical sector in various roles in Regulatory Affairs, R&D, Project Management and Clinical research. Together with her then business partner, Kay ran her own Regulatory Affairs consultancy company, Ivowen for 9 years before joining EirGen Pharma in 2010 where she held the role of Head of Scientific Affairs as part of the Senior Leadership Team until her departure in June 2019. As part of her role at EirGen, Kay was responsible Regulatory and Clinical Affairs and for setting up a Project Management Office (PMO) for the company to enable delivery of projects on multiple platforms including Oral Solid Dose (OSD), Sterile Fill Finish (aseptic line), innovative Veterinary drugs in the small animal space and innovative modified release OSD formulations for EirGen’s parent company, OPKO. Various other roles throughout those 32 years included working as an analytical development chemist in a laboratory at generics company, Clonmel Healthcare (platforms included OSD and oral liquids), managing an inhalations R&D laboratory at IVAX and managing a Regulatory Affairs department including management of Bioequivalence studies and an R&D laboratory at Niche Generics.